Throat Fullness: Drugs That Cause or Treat It

What Is Throat Fullness (Globus Pharyngeus)?

Globus pharyngeus describes a persistent or intermittent sensation of a lump, tightness, or fullness in the throat that occurs without any actual obstruction to swallowing. The sensation typically worsens between meals and improves during eating. It is not painful.

The term replaced the older "globus hystericus" label after research showed that most cases have an identifiable physiological contributor rather than a purely psychogenic origin 1. A 2012 systematic review in Clinical Otolaryngology reported that globus accounted for approximately 4% of new ENT referrals in the UK, with a lifetime prevalence that some population surveys place as high as 45% 1. Women and men are affected at roughly equal rates, though women seek care more frequently.

The pathophysiology is multifactorial. Proposed mechanisms include upper esophageal sphincter (UES) hypertonia, laryngopharyngeal reflux (LPR), esophageal dysmotility, and pharyngeal hypersensitivity driven by visceral hyperalgesia 2. The Rome IV criteria classify globus as a functional esophageal disorder when structural and mucosal causes have been excluded 2. This classification matters because it directs treatment toward neuromodulation rather than acid suppression alone.

Medications That Can Cause or Worsen Throat Fullness

Several drug classes produce throat fullness through distinct pharmacological pathways. Identifying a medication trigger can resolve the symptom entirely, sparing patients months of unnecessary workup.

ACE inhibitors (enalapril, lisinopril, ramipril) cause throat irritation and a sensation of swelling via bradykinin accumulation in the pharyngeal mucosa. ACE-inhibitor-related cough affects 5 to 35% of users 3, and the same bradykinin-mediated pathway produces globus-like symptoms in a smaller subset. Angioedema, a rare but serious complication occurring in 0.1 to 0.7% of ACE inhibitor users, can present initially as throat fullness before progressing to visible swelling 3.

Oral bisphosphonates (alendronate, risedronate) can cause esophageal irritation, erosive esophagitis, and a persistent feeling of a pill being "stuck." A post-marketing analysis submitted to the FDA documented esophageal adverse events in approximately 1 in 10,000 alendronate users 4. Proper administration (upright posture, full glass of water, 30 minutes before lying down) reduces this risk substantially.

Inhaled corticosteroids (fluticasone, budesonide) deposit on pharyngeal and laryngeal tissue, causing local candidiasis and mucosal irritation in 5 to 10% of users 5. This produces a scratchy, full sensation in the throat. Using a spacer device and rinsing the mouth after inhalation mitigates the problem.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) slow gastric emptying and may worsen or unmask laryngopharyngeal reflux. In the STEP-1 trial (N=1,961), nausea occurred in 44.2% and dyspepsia in 9.0% of participants receiving semaglutide 2.4 mg 6. While globus was not a prespecified endpoint, gastrointestinal complaints including "throat discomfort" appeared in post-marketing surveillance reports to the FDA. GLP-1-mediated delayed gastric emptying increases the volume of gastric contents available for reflux into the proximal esophagus and hypopharynx.

Other contributors include iron supplements (direct mucosal irritation), doxycycline (pill esophagitis), potassium chloride tablets (erosive contact), and anticholinergic medications that reduce saliva production and impair the pharyngeal clearance mechanism.

How Laryngopharyngeal Reflux Connects Drugs to Globus

Laryngopharyngeal reflux (LPR) serves as the most common bridge between medication use and throat fullness. Unlike classic gastroesophageal reflux disease (GERD), LPR often presents without heartburn. The primary symptoms are throat clearing, hoarseness, postnasal drip sensation, and globus.

A prospective study published in the American Journal of Gastroenterology found that 37 to 68% of patients with globus had abnormal pharyngeal acid exposure on dual-probe pH monitoring 7. The pepsin enzyme, carried in refluxate, damages laryngeal epithelium at pH levels as high as 6.0, well within the "non-acidic" range that standard pH testing may miss 7.

Medications that relax the lower esophageal sphincter (calcium channel blockers, nitrates, benzodiazepines, progesterone-containing HRT) or delay gastric emptying (opioids, GLP-1 agonists) increase the reflux burden. The 2020 British Laryngological Association (BLA) position statement, authored by Dr. Martin Birchall and colleagues, noted: "Clinicians should perform a medication review in all patients presenting with globus, as drug-induced LPR is a modifiable contributor that is frequently overlooked" 8.

Dr. Peter Belafsky, developer of the Reflux Symptom Index (RSI), has stated: "Globus is the single most common presenting symptom of laryngopharyngeal reflux, reported by over 90% of LPR patients in our clinic population" 9.

Proton Pump Inhibitors as First-Line Treatment

Empiric PPI therapy is the most widely used first-line approach for globus pharyngeus associated with suspected reflux. The rationale is straightforward: suppress acid, reduce pepsin activation, and allow pharyngeal mucosa to heal.

A randomized controlled trial by Wo and colleagues (N=145) compared lansoprazole 30 mg twice daily to placebo for suspected LPR-related throat symptoms over 16 weeks. The trial found no statistically significant difference between lansoprazole and placebo for the composite laryngeal symptom score (P=0.16) 10. This result has been replicated in several subsequent trials, raising questions about empiric PPI use in the absence of documented acid exposure.

Despite mixed trial data, clinical guidelines from the American Academy of Otolaryngology (AAO-HNS) still recommend a time-limited empiric PPI trial (twice-daily dosing for 8 to 12 weeks) as a reasonable first step, particularly when flexible laryngoscopy shows posterior laryngeal edema or erythema 11. The logic is pragmatic. PPIs are inexpensive, widely available, and carry low short-term risk.

Standard empiric regimens include omeprazole 20 mg twice daily, esomeprazole 40 mg once daily, or lansoprazole 30 mg twice daily, all taken 30 to 60 minutes before meals. Patients who fail to respond after 8 weeks should not continue PPIs indefinitely. Instead, they should be referred for ambulatory reflux monitoring with impedance-pH testing to determine whether reflux is actually present 11.

Long-term PPI use carries documented associations with hypomagnesemia, Clostridioides difficile infection, and reduced calcium absorption 12. The FDA issued a safety communication in 2010 regarding the possible increased risk of fractures with prolonged PPI use 12. These risks reinforce the importance of limiting empiric courses rather than using PPIs as indefinite therapy for globus.

Neuromodulators: Tricyclic Antidepressants and SSRIs

When reflux testing is negative or PPIs fail, neuromodulators become the next therapeutic tier. The rationale shifts from acid suppression to addressing visceral hypersensitivity, the heightened perception of normal pharyngeal sensations that characterizes functional globus.

Low-dose amitriptyline (10 to 25 mg nightly) is the most studied tricyclic for functional esophageal disorders. A randomized, double-blind, placebo-controlled trial published in Gastroenterology (N=75) demonstrated that amitriptyline 25 mg reduced functional chest pain episodes by 50% compared to placebo over 4 weeks, with secondary improvements in globus scores 13. The mechanism involves central downregulation of visceral afferent signaling rather than any antidepressant effect, which is why subtherapeutic doses (below the 75 to 150 mg range used for depression) are effective.

SSRIs have a thinner evidence base for globus specifically, though they are used in practice. A small open-label Korean study (N=28) found that citalopram 20 mg daily for 8 weeks produced "much improved" or "very much improved" ratings on the Clinical Global Impression scale in 61% of participants with refractory globus 14. Sertraline and escitalopram are also used off-label at standard antidepressant doses.

Gabapentin and pregabalin represent emerging options for pharyngeal neuropathic pain and hypersensitivity. A retrospective case series (N=32) of patients with neuropathic throat symptoms found that gabapentin (300 to 900 mg three times daily) produced symptom improvement in 68% of patients over 6 months 15. These agents may be particularly useful in patients whose globus follows upper respiratory infection, intubation, or cervical spine surgery, scenarios suggesting vagal or superior laryngeal nerve irritation.

Side effects limit use. Amitriptyline causes dry mouth, constipation, and morning sedation. SSRIs may worsen GERD by reducing lower esophageal sphincter pressure. Gabapentin causes dizziness and weight gain. Selecting the right neuromodulator requires matching the side-effect profile to the patient's comorbidities.

Behavioral and Non-Pharmacological Approaches

Speech-language pathology (SLP) and cognitive behavioral therapy (CBT) address the neuromuscular and psychological components of globus, respectively. These are not alternative medicine. They have controlled trial data.

A randomized controlled trial by Khalil and colleagues (N=90) compared SLP-directed laryngeal manual therapy and vocal hygiene education to reassurance alone. At 6 months, 62% of the SLP group reported complete symptom resolution versus 32% in the control group (P <0.01) 16. SLP techniques include laryngeal massage to reduce UES tension, diaphragmatic breathing to decrease supraglottic compression, and exercises that interrupt the throat-clearing cycle.

CBT targets the hypervigilance and catastrophic interpretation that maintain globus in many patients. A Danish pilot trial (N=36) found that 4 sessions of throat-focused CBT reduced Glascow-Edinburgh Throat Scale (GETS) scores by 41% from baseline 17. The overlap between globus and anxiety is well documented: a meta-analysis reported that 60.1% of globus patients met criteria for an anxiety or depressive disorder, compared to 22.6% of controls 17.

Dietary modifications play a supporting role. Reducing caffeine, alcohol, carbonated beverages, and late-evening meals can lower the reflux burden. Alkaline water (pH 8.0 or above) has been proposed to inactivate pepsin in the hypopharynx, though large-scale trial data are lacking.

The Diagnostic Workup: When to Investigate Further

Not every patient with throat fullness needs extensive testing. The initial evaluation should distinguish globus from dysphagia (difficulty moving food from mouth to stomach), which carries a different and more concerning differential diagnosis.

Flexible nasolaryngoscopy (FNL) is the standard first-line investigation. It is performed in the office, takes under 5 minutes, and allows direct visualization of the larynx, hypopharynx, and base of tongue. Red flags on FNL include mucosal lesions, asymmetric vocal fold movement, pooling of secretions in the pyriform sinuses, and submucosal masses.

The American Academy of Otolaryngology recommends further investigation with barium swallow or esophagogastroduodenoscopy (EGD) when any of the following are present: dysphagia, odynophagia (painful swallowing), unintentional weight loss, hematemesis, lateralizing throat symptoms, or cervical lymphadenopathy 11. Age alone (over 50) is considered a relative indication for EGD given the increased baseline risk of esophageal pathology.

Ambulatory 24-hour impedance-pH monitoring is reserved for patients who fail empiric PPI therapy. This test captures both acidic and non-acidic (weakly acidic) reflux events reaching the proximal esophagus and can confirm or exclude reflux as the cause. High-resolution esophageal manometry identifies motility disorders such as cricopharyngeal dysfunction or esophageal spasm.

Thyroid evaluation (palpation, TSH, and ultrasound if a nodule is suspected) should be performed in patients with anterior neck fullness, given that thyroid nodules are palpable in 4 to 7% of the adult population and can mimic globus 18.

Medications Under Investigation

Several agents are being studied for globus and related functional throat disorders that have no current FDA indication for this use.

Baclofen, a GABA-B receptor agonist, reduces transient lower esophageal sphincter relaxations (TLESRs) by 40 to 60% in pharmacodynamic studies 19. A pilot crossover trial showed reduced LPR symptom scores with baclofen 10 mg three times daily, though CNS side effects (drowsiness, dizziness) limit tolerability.

Botulinum toxin injection into the cricopharyngeus muscle is used for cricopharyngeal dysfunction and has been reported in case series to relieve globus when UES hypertonia is documented on manometry. A systematic review of 68 cases found symptom improvement in 74% of patients, with effects lasting 3 to 6 months 20.

Alginate-based formulations (sodium alginate combined with potassium bicarbonate, marketed as Gaviscon Advance in the UK) form a physical raft over gastric contents and may reduce LPR-related globus. A UK-based randomized trial (N=49) found that liquid alginate reduced RSI scores by 8.2 points compared to 2.1 points with placebo over 2 months (P=0.004) 21.

Research into mucosal-protective agents, pharyngeal-targeted pepsin inhibitors, and vagal neuromodulation devices is ongoing, though none have progressed beyond early-phase trials for globus as a primary indication.

A Practical Drug-Review Checklist for Clinicians

Before initiating new therapy for throat fullness, a structured medication review can identify reversible drug-induced contributors. Any patient on an ACE inhibitor should trial an angiotensin receptor blocker (ARB) as a switch. Bisphosphonate users with esophageal symptoms may benefit from switching to intravenous zoledronic acid (5 mg annually) or denosumab, eliminating direct esophageal contact. Inhaled corticosteroid users should verify spacer technique and mouth-rinsing compliance. GLP-1 agonist users with new-onset globus should be evaluated for LPR with a trial of twice-daily PPI before attributing the symptom to the injectable alone. If the throat fullness persists 8 weeks after removing or replacing the suspected agent, pursue formal ENT evaluation with flexible nasolaryngoscopy.